Aspect Biosystems, a Vancouver, BC, Canada-based biotechnology company developing bioprinted tissue therapeutics for the regenerative medicine, raised US$115M in Series B funding.
The round was led by Dimension, with participation from existing and new investors including Novo Nordisk, Radical Ventures, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund. Concurrent with the financing, Nan Li, Founder & Managing Partner at Dimension, was appointed to the Company’s Board of Directors.
The company intends to use the funds to advance multiple bioprinted tissue therapeutics towards the clinic with a mission to deliver a new class of cellular medicines and functional cures for people living with serious metabolic and endocrine diseases.
Led by CEO and Founder Tamer Mohamed, Aspect Biosystems is a biotechnology company providing the development of bioprinted tissue therapeutics for elusive diseases. Its bioprinted tissue therapeutics are designed to replace, repair, or supplement biological function inside the body. Aspect is creating these new cell therapies by applying its full-stack tissue therapeutic platform, which integrates proprietary AI-powered bioprinting technology, computational design tools, therapeutic cells, and advanced biomaterials.
Aspect is advancing a pipeline of bioprinted tissue therapeutics across multiple disease areas in the endocrine and metabolic space including diabetes, obesity, rare endocrine disorders, and liver disease.
FinSMEs
09/01/2025